Disc Medicine (IRON) Insider Nadim Ahmed Buys 5,176 Shares
Nadim Ahmed purchased 5,176 shares of Disc Medicine, Inc. on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Nadim Ahmed bought 5,176 shares of Disc Medicine, Inc. ($IRON) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IRON is down 0.9% after 1 week, up 5.1% after 1 month and down 19.7% to date (from the $70.79 close on Jun 18, 2026).
IRON
Disc Medicine, Inc.
Key Points
- Nadim Ahmed bought 5,176 shares of Disc Medicine, Inc. on June 18, 2026.
- Shares of NASDAQ:IRON traded near $70.8 on Wednesday with a market cap of $2.7 billion.
- Analysts maintain a strong buy consensus with a target mean price of $101.55.
Get $IRON trade alerts by text
We text you when insiders, Congress or big funds trade $IRON. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Disc Medicine, Inc. alert may contain errors. Disclosures
Nadim Ahmed purchased 5,176 shares of Disc Medicine, Inc. (NASDAQ:IRON) on June 18, 2026. This insider buy was not part of a planned trading program. The stock traded around $70.8 on Wednesday.
Insider Buying and Selling at Disc Medicine, Inc.
In addition to Nadim Ahmed's recent purchase, several other insiders were active on June 18, 2026. Liam Ratcliffe also bought 6,212 shares, while Rahul Khara, the Chief Legal Officer, acquired 7,500 shares at an average price of $14.69. Meanwhile, John Quisel, the CEO, sold 34,000 shares under a planned selling program at a price of $70.22, but also made a non-planned purchase of the same amount at $9.86.
Disc Medicine, Inc. Stock Up 1.8%
Shares of Disc Medicine, Inc. traded near $70.8 on Wednesday. The company has a market capitalization of approximately $2.7 billion. The stock's forward P/E ratio is not meaningful as the company is not currently profitable. Disc Medicine has a beta of 2.101, indicating it is more volatile than the overall market. The stock's 52-week range is between $40.0 and $99.5, with a 50-day moving average of $68.55 and a 200-day moving average of $73.16. The company maintains a strong liquidity position with a current ratio of 24.002 and a quick ratio of 23.446.
Analysts Set New Price Targets
On June 16, 2026, Morgan Stanley maintained its buy rating on Disc Medicine with a price target of $85. Other firms such as Wells Fargo and Truist Securities have also kept their buy ratings, with price targets of $79 and $83 respectively. Analysts' consensus is a strong buy, with the stock's mean target price at $101.55 based on 11 opinions.
About Disc Medicine
Disc Medicine, Inc., headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing treatments for serious blood disorders. Founded in 2017, the company targets diseases related to red blood cell formation and function. Its pipeline includes bitopertin for various types of anemia, DISC-0974 for anemia in myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera. Disc Medicine employs 154 people under the leadership of CEO Dr. John D. Quisel.
Bottom Line
Nadim Ahmed's insider purchase of Disc Medicine shares signals interest in the company's potential. Investors often track such moves from insiders to gauge confidence in the company's prospects. Disc Medicine's stock remains volatile, reflecting its developmental stage in the biotechnology sector. Analysts continue to show strong support with buy ratings and high target prices.
Related Filing Alerts
Source: Nadim Ahmed's Form 4 filing on $IRON (Jun 18, 2026). Find the original filing: IRON Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts